BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tanabe Pharma Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Tanabe Pharma Corporation's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06496243-401@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT06496243)
DESCRIPTION:Obicetrapib\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Level
 s\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06496243
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202509-401@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT05202509)
DESCRIPTION:Obicetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapi
 b in Patients With Cardiovascular Disease\nEstimated primary completion: N
 ovember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obicetr
 apib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05202509
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03817502-803@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT03817502)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Schizophrenia.\nStudy: Effica
 cy and Safety of Cariprazine in the Treatment of Adolescent Participants (
 13 to 17 Years of Age) With Schizophrenia\nEstimated primary completion: 1
 5 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cari
 prazine-vraylar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03817502
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04777357-803@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT04777357)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Bipolar Disorder.\nStudy: A S
 tudy to Assess Change in Disease Activity and Adverse Events (AEs) With Ca
 riprazine in the Treatment of Depressive Episodes in Pediatric Participant
 s Participants (10 to 17 Years of Age) With Bipolar I Disorder.\nEstimated
  primary completion: March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cariprazine-vraylar#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04777357
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549258-5632@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT05549258)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study of Inebilizumab in Pediat
 ric Subjects With Neuromyelitis Optica Spectrum Disorder\nEstimated primar
 y completion: 13 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05549258
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219602-401@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT07219602)
DESCRIPTION:Obicetrapib\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Eva
 luate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or 
 Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering The
 rapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07219602
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312189-9342@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ingrezza (Valbenazine): Phase 3 readout est. (NCT06312189)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 3\, Huntington's Disease.\nStudy
 : Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Pa
 rticipants With Chorea Associated With Huntington Disease in Canada\nEstim
 ated primary completion: April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/valbenazine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06312189
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5632@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Inebilizumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794670-401@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT07794670)
DESCRIPTION:Obicetrapib\, phase 2.\nStudy: Randomized Study to Evaluate the
  Effect of Obicetrapib in Participants With Preclinical Alzheimer's Diseas
 e\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07794670
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987539-5632@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06987539)
DESCRIPTION:Inebilizumab\, phase 2\, Generalized Myasthenia Gravis.\nStudy:
  A Study to Evaluate the Pharmacokinetics\, Pharmacodynamics\, Safety and 
 Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravi
 s (gMG)\nEstimated primary completion: 13 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06987539
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165028-115@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tirzepatide (Mounjaro): Phase 3 readout est. (NCT07165028)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 3.\nStudy: A Master Protocol of 
 Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic 
 Liver Disease (SYNERGY-Outcomes)\nEstimated primary completion: August 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounja
 ro#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7165028
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222553-5632@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20310610
DTEND;VALUE=DATE:20310611
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT07222553)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study to Evaluate the Pharmacok
 inetics\, Pharmacodynamics\, Safety\, and Tolerability of Inebilizumab in 
 Pediatric Participants With IgG4-RD\nEstimated primary completion: 10 June
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222
 553
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598825-5632@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07598825)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Trial of Inebilizumab in Part
 icipants With Autoimmune Hepatitis\nEstimated primary completion: 30 July 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075988
 25
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851220-5632@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20310927
DTEND;VALUE=DATE:20310928
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07851220)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Phase 3 Study of Inebilizumab
  in Participants With Primary Membranous Nephropathy\nEstimated primary co
 mpletion: 27 September 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07851220
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
